Staff Profile

Introduction

Herbie Newell is Professor of Cancer Therapeutics. He has over 40 years experience of the discovery and development of conventional and novel cancer chemotherapies.

Roles and Responsibilities

Professor of Cancer Therapeutics
Northern Institute for Cancer Research

Qualifications

1979 Institute of Biology - Membership by examination in Pharmacology

1984 University of London - PhD Pharmacology

2011 Academy of Medical Sciences - Fellow

Previous Positions

2009-Date Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Professor of Cancer Therapeutics

2006-2009 Cancer Research UK, London, Interim Executive Director of Clinical and Translational Research and Director of Translational Research (0.6 FTE)

2003-2006 Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne, Scientific Director and Professor of Cancer Therapeutics

1995-2003 Cancer Research Unit, University of Newcastle, Newcastle upon Tyne, Associate and Acting Director, Professor of Cancer Therapeutics

1989-1995 Cancer Research Unit, University of Newcastle, Newcastle upon Tyne, Senior Lecturer

1988-1989 Clinical Pharmacology Team, Drug Development Section, Institute of Cancer Research, Sutton, Surrey, Grade 1 Scientist

1984-1988 Department of Biochemical Pharmacology, Institute of Cancer Research, Sutton, Surrey, Grade 2 Scientist

1976-1984 Department of Biochemical Pharmacology, Institute of Cancer Research, Sutton, Surrey, Research Officer

Memberships

Past - Chair and Member of numerous CR UK, NCRI, EORTC, UK and non-UK University and Government Institute review committees

Past - HEFCE RAE 2008 UoA 2 (Cancer Studies) Panel Member

Past - HEFCE RAE 2001 UoA 9 (Pharmacy) Panel Member

Current - Chair MRC DPFS/DCS Panel

Current – Chair CRT Pioneer Fund Scientific Advisory Board        

Current - Chair NIHR Manchester Musculoskeletal BRU Scientific Advisory Board

Current – Chair Ontario Institute for Cancer Research High Impact Clinical Trials Program Scientific Advisory Board

Member – CRT Discovery Laboratory Scientific Advisory Board

Member - IMI QuIC-ConCePT Scientific Advisory Board

Member - British Association for Cancer Research

Member - American Association for Cancer Research

Languages

English

Research Interests

Cancer pharmacology
Drug development
Pharmacokinetics of anticancer drugs
DNA repair modulation
Kinase inhibitors

Other Expertise

Translational cancer research
Early clinical trials in cancer

Current Work

The development of inhibitors of:
Cyclin dependent kinases
DNA damage related kinases
Receptor tyrosine kinases
DNA repair enzymes and proteins
Pharmacologically-guided dosing in adults and children

Future Research

The development of:
Selective antitumour agents
Non-invasive imaging methodology for pharmacokinetic and pharmacodynamic studies

Research Roles

Professor of Cancer Therapeutics
Northern Institute for Cancer Research

Postgraduate Supervision

PhD Student Supervisor

Esteem Indicators

2004 Michel Clavel Award Lecturer at the 16th EORTC/NCI/AACR New Drugs Conference, Geneva

Funding

"Newcastle Paediatric Pharmacology UKCCSG - CRC Site Visit" Cancer Research Campaign. Jan 2000 - Jan 2004. £71,130 per annum. Held with AV Boddy and ADJ Pearson.

"Synthesis and evaluation of novel inhibitors of DNA-dependent protein kinase (DNA-PK)" BBSRC Industrial CASE studentship with KuDOS Pharmaceuticals. Oct 2000 - Oct 2003. £54,210. Held with AH Calvert, NJ Curtin, BT Golding and RJ Griffin.

"Combinatorial synthesis of libraries of small molecule modulators of signal transduction pathways" EPSRC quota studentship. Oct 2000 - Oct 2003. £40,000. Held with (PI) AH Calvert, NJ Curtin, BT Golding, RJ Griffin and I Hardcastle.

"Potentiation of thymidylate synthase inhibition by tumour-specific thymidine depletion" Cancer Research Campaign. Oct 2000 - Oct 2003. £44,461. Held with AV Boddy and GA Taylor.

"Design and synthesis of selective DNA-dependent protein kinase (DNA-PK) inhibitors" Cancer Research Campaign. Oct 2001 - Oct 2004. £64,000. Held with AH Calvert, NJ Curtin, BT Golding, RJ Griffin and IR Hardcastle.

"The synthesis of DNA-dependent protein kinase inhibitors" KuDOS pharmaceuticals. Equipment grant, 2001. £62,000. Held with AH Calvert, NJ Curtin, BT Golding RJ Griffin and IR Harcastle.

"Development of pharmacodynamic assays for the clinical evaluation of novel PARP inhibitors, and pre-clinical investigations of backup compounds" Agouron Pfizer GRD. Jan 2001-Jan 2002. £107,500. Held with AV Boddy, NJ Curtin, AH Calvert and BW Durkacz.

"Clerical support in recognition of contributions to CRC Committees" Cancer Research Campaign. Sept 2000 - Date. £14,818 per annum.

"Molecular Mechanisms of Disease Progression and Novel Treatments for Prostate Cancer" NCRI/MRC. Oct 2001 - Oct 2006. £1,627,389. Held with IR Hardcastle, HY Leung, DE Neal and CN Robson.

"Design, synthesis and evaluation of novel CDK inhibitors" AstraZeneca Pharmaceuticals. 2002-2004. £100,000. Held with AH Calvert, NJ Curtin, RJ Griffin, BT Golding and IR Hardcastle.:

"Preclinical and pharmacodynamic studies with novel DNA-PK inhibitors" KuDos Pharmaceuticals. Jan 2002 - Jan 2004. £183,394. Held with AH Calvert, NJ Curtin, BW Durkacz, BT Golding RJ Griffin and IR Hardcastle.

"Cancer Research UK Developmental Therapeutics Programme" Joint Director with AH Calvert. Oct 2002 - Sept 2007. £1,000,000 per annum.

"Establishment of Newcastle as a National Translational Cancer Research Network (NTRAC) Centre. Department of Health. Held with AV Boddy, AH Calvert, A Chippendale, HY Leung, D Ellison, M Verrill. June 2003 - May 2008. £1,080,000.

Industrial Relevance

Member of Scientific Advisory Panels for:
Astex Technology, AstraZenenca, Eisia Pharmaceuticals, OSI Pharmaceuticals, Viscum AG, Xenova

Patents

JONES T.R., JACKMAN A.L. and NEWELL D.R. (1986): Anticancer quinazoline derivatives. UK and Foreign Patent No. 8513754.

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R., AND GOLDING, B. T. Benzamide Analogues ADPRT (PARP) Inhibitors Patent Application Number PCT/GB95/00513

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Benzimidazole PARP Inhibitors. Patent Application Number PCT/GB96/01832.

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Prodrugs of PARP Inhibitors. Patent Application Number 9702701.5

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Pyrimidopyrimidine Compounds. Patent Application Number 9706618.7.

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T., ENDICOTT, J.A., NOBLE, M.E.M., BOYLE, F.T. AND JEWSBURY, P.J. Purine CDK Inhibitors. Patent Application Number 9714603.9

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. ENDICOTT, J.A., NOBLE, M.E.M., BOYLE, F.T. AND JEWSBURY, P.J. Pyrimidine CDK Inhibitors. Patent Application Number 9806739.0

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Dipyridamole analogues. Patent Application Number PCT/GB98/00966

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Anilinopurine CDK inhibitors. Patent Application Number PCT/GB01/101686.4

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R., GOLDING, B. T. HARDCASTLE, I.R., MARTIN, N., SMITH, G.C.M., RAYNAUD, F. AND WORKMAN, P. DNA-PK inhibitors - 1. Patent Application Number PCT/GB01/19865.4

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R., GOLDING, B. T. HARDCASTLE, I.R., MARTIN, N., SMITH, G.C.M., RAYNAUD, F. AND WORKMAN, P. DNA-PK inhibitors - 2. Patent Application Number PCT/GB01/19863.9

WALLING, J.M., WEBB, H.K., CALVERT, A.H. AND NEWELL, D.R. Lometrexol combination therapy. Patent Application Number 10/010,740.

• Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L, Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson CN. Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One 2012, 7(10), e45539.
• Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson C, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear KA, Slade A, Thommes P, Martin NMB, Newell DR, Smith GCM, Curtin NJ. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics 2012, 11(8), 1789-1798.
• Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
• Alhasan SF, Beale GS, Newell DR, Reeves HL. Suppression of SULF2, an extracellular endosulfatase up-regulated in hepatocellular cancers, modulates WNT signalling and inhibits cell growth. In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer 2012, 106(8), 1386-1394.
• de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JAE. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leukemia Research 2011, 35(9), 1233-1240.
• Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine 2011, 17(7), 875-882.
• Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J. Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency. Journal of Medicinal Chemistry 2011, 54(5), 1233-1243.
• Watson AF, Liu JF, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu XH, McDonnell JM, Newell DR, Noble MEM, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR. MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones. Bioorganic & Medicinal Chemistry Letters 2011, 21(19), 5916-5919.
• Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein. Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
• Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, Angibaud P, Perera T, Fazal L, Ross D, Jones CG, Madin A, Benning RK, Vickerstaffe E, O'Brien A, Frederickson M, Reader M, Hamlett C, Batey MA, Rich S, Carr M, Miller D, Feltell R, Thiru A, Bethell S, Devine LA, Graham BL, Pike A, Cosme J, Lewis EJ, Freyne E, Lyons J, Irving J, Murray C, Newell DR, Thompson NT. Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models. Molecular Cancer Therapeutics 2011, 10(9), 1542-1552.
• Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer 2011, 47(13), 2052-2059.
• Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV. Thiothymidine combined with UVA as a potential novel therapy for bladder cancer. British Journal of Cancer 2011, 104(12), 1869-1876.
• Meschini E, Endicott JA, Golding BT, Hardcastle IR, Newell DR, Noble MEM, Wang LZ, Griffin RJ. Design and synthesis of dual CDK2 and CDK7 inhibitors. In: Abstracts of Papers of the American Chemical Society. 2010, American Chemical Society.
• Clapham KM, Rennison T, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Golding BT, Hardcastle IR, Newell DR, Cano C, Griffin RJ. Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK). In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ. DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry 2010, 53(24), 8498-8507.
• Carbain B, Roche C, Endicott JA, Golding BT, Hardcastle IR, Cano C, Zhen-Wang L, Newell DR, Noble MEM, Griffin RJ. Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors. In: European Journal of Cancer Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin: Elsevier.
• Cornell L, Munck JM, Budhisetiawan F, Newell DR, Bardos JI, Manas D, Curtin NJ, Reeves H. Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases. 2010, Boston, MA: Hepatology: Wiley-Blackwell.
• Watson AF, Golding BT, Griffin RJ, Hutton C, Liu JF, Lug XH, Lunec J, Newell DR, Valeur E, Hardcastle IR. MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. In: Abstracts of Papers of the American Chemical Society: 236th National Meeting of the American Chemical Society. 2008, Philadelphia, Pennsylvania, USA: American Chemical Society.
• Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96(1), 56-67.
• Newell DR, Silvester J, McDowell C, Burtles SS. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. European Journal of Cancer 2004, 40(6), 899-906.
• Wells, P., Aboagye, E., Gunn, R., Osman, S., Boddy, A. V., Taylor, G. A., Rafi, I., Hughes, A. N., Calvert, A. H., Price, P., Newell, D. R. 2-[¹¹C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. Journal of the National Cancer Institute 2003, 95(9), 675-682.
• Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology 2002, 9(10), 745-749.
• Davies TG, Endicott JA, Noble ME, Johnson LN, Arris CE, Bentley J, Boyle FT, Calvert AH, Curtin NJ, Jewsberry PJ, Gibson AE, Golding BT, Griffin RJ, Hardcastle I, Mesguiche V, Parsons R, Whitfield H, Newell DR. Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design. Cellular and Molecular Biology Letters 2001, 6(2B), 514-515.
• Davies TG, Endicott JA, Johnson LN, Noble ME, Arris CE, Bentley J, Calvert AH, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IH, Mesguiche V, Newell H, Parsons RJ, Whitfield HJ, Boyle T, Jewsbury P. Structure based design of a potent inhibitor of cdk2. Cellular and Molecular Biology Letters 2001, 6(2B), 470.
• Griffin RJ, Arris CE, Calvert AH, Curtin NJ, Jewsbury P, Endicott JA, Gibson AE, Boyle FT, Golding BT, Grant S, Johnson LN, Noble MEM, Newell DR, Lawrie A. Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society 2000, 219(2), U55 296-MEDI.
• Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble MEM, Sausville EA, Schultz R, Yu W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
• Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research 2000, 6, 328.
• Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica 2019, 104(9), 1804-1811.
• Coxon RC, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget 2017, 8, 19089-19124.
• Drummond CJ, Esfandiari A, Liu J, Lu X, Hutton C, Jackson J, Bennaceur K, Xu Q, Makimanejavali AR, Bello FD, Piergentili A, Newell DR, Hardcastle IR, Griffin RJ, Lunec J. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Oncotarget 2016, 7(29), 46203-46218.
• Beale G, Haagensen E, Thomas H, Wang LZ, Revill C, Payne S, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer. British Journal of Cancer 2016, 115, 682-690.
• Reuillon T, Alhasan SF, Beale GS, Bertoli A, Brennan A, Cano C, Reeves HL, Newell DR, Golding BT, Miller DC, Griffin RJ. Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. Chemical Science 2016, 7(4), 2821-2826.
• Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemotherapy and Pharmacology 2016, 78(6), 1269-1281.
• Pearson RA, Thelwall PE, Snell J, McKenna J, Pieniazek P, Fitzgerald E, Heer R, McMenemin RM, Pedley ID, Azzabi A, Maxwell RJ, Newell DR, Plummer ER, Frew JA. Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study. In: Genitourinary Cancers Symposium 2016. 2016, San Francisco, California: Journal of Clinical Oncology.
• Myers SM, Bawn RH, Bisset LC, Blackburn TJ, Cottyn B, Molyneux L, Wong AC, Cano C, Clegg W, Harrington RW, Leung H, Rigoreau L, Vidot S, Golding BT, Griffin RJ, Hammonds T, Newell DR, Hardcastle IR. High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors. ACS Combinatorial Science 2016, 18(8), 444-455.
• Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. European Journal of Cancer 2016, 56, 69-76.
• Alhasan SF, Haugk B, Ogle LF, Beale GS, Long A, Burt AD, Tiniakos D, Televantou D, Coxon F, Newell DR, Charnley R, Reeves HL. Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer 2016, 115(7), 797-804.
• Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Cell Cycle 2016, 15(4), 506-518.
• Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL. DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research 2015, 21(4), 925-933.
• Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble MEM, Wedge SR, Endicott JA, Griffin RJ. Identification and characterization of an irreversible inhibitor of CDK2. Chemistry & Biology 2015, 22(9), 1159-1164.
• Vormoor B, Schlosser Y, Blair H, Wilkinson S, Newell DR, Curtin N. Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy. In: 47th Congress of the International Society of Paediatric Oncology (SIOP). 2015, Cape Town, South Africa: Wiley-Blackwell.
• Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget 2015, 6(12), 10207-10221.
• Miller DC, Carbain B, Beale GS, Alhasan SF, Reeves HL, Baisch U, Newell DR, Golding BT, Griffin RJ. Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases. Organic & Biomolecular Chemistry 2015, 13(18), 5279-5284.
• Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach. Chemical Biology and Drug Discovery 2015, 86(2), 180-189.
• Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer Letters 2015, 363(1), 37-45.
• Shouksmith AE, Evans LE, Tweddle DA, Miller DC, Willmore E, Newell DR, Golding BT, Griffin RJ. Synthesis and Activity of Putative Small-​Molecule Inhibitors of the F-​Box Protein SKP2. Australian Journal of Chemistry 2015, 68(4), 660-679.
• Carbain B, Paterson DJ, Anscombe E, Campbell AJ, Cano C, Echalier A, Endicott JA, Golding BT, Haggerty K, Hardcastle IR, Jewsbury PJ, Newell DR, Noble MEM, Roche C, Wang LZ, Griffin RJ. 8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode. Journal of Medicinal Chemistry 2014, 57(1), 56-70.
• Anil B, Blackburn E, Blackburn T, Cully S, Liu J, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lunec J, Newell DR, Revill CH, Riedinger C, Watson AF, Xu Q, Zhao Y, Hardcastle IR, Noble MEM. An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
• Lebraud H, Golding BT, Meschini E, Cano C, Anscombe E, Wang LZ, Endicott JA, Noble MEM, Newell DR, Griffin RJ. Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors. In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
• Shouksmith AE, Evans LE, Griffin RJ, Golding BT, Newell H, Miller DC, Noble MEM, Endicott JA, Tweddle D. Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex. In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
• Myers S, Martin N, Bawn R, Blackburn T, Barrett L, Reuillon T, Golding B, Griffin R, Hammonds T, Hardcastle I, Leung H, Newell D, Rigoreau L, Wong A, Cano C. Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy. In: 26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
• Pecqueur J, Vormoor B, Zhao Y, Newell H. Evaluating the activity of the p53-MDM2 inhibitor NDD0005 in Ewing sarcoma. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Theraputics. 2014, Barcelona, Spain: Elsevier.
• Martin M, Anscombe E, Meschini E, Staunton D, Geitmann M, Danielson UH, Wang LZ, Vidal RM, Reuillon T, Golding BT, Newell DR, Wedge S, Noble MEM, Endicott JA, Griffin RJ. Identification and characterization of an irreversible inhibitor of CDK2. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
• Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochemical Pharmacology 2014, 88(1), 58-65.
• Figg WD, Newell DR. Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine. Clinical Cancer Research 2014, 20(10), 2525-2529.
• Tudhope S, Zhao Y, Wittner A, Wilmore E, Bertoli A, Adhikari S, Harnor SJ, Del Bello F, Piergentili A, Lunec J, Hardcastle IR, Griffin RJ, Golding BR, Cano C, Newell DR, Wedge SR. Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
• Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. British Journal of Cancer 2014, 111, 716-725.
• Harnor SJ, Rennison T, Galler M, Cano C, Griffin RJ, Newell DR, Golding BT. Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [¹⁸F]FLT. MedChemComm 2014, 5(7), 984-988.
• Bertoli A, Adhikari S, Harnor SJ, Zhao Y, Lunec J, Wedge SR, Tudhope S, Wittner A, Golding BT, Hardcastle IR, Cano C, Newell DR, Griffin RJ. Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction. In: 247th ACS National Meeting and Exposition. 2014, Dallas, TX, USA: American Chemical Society.
• Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GCM, Thommes P, Ting A, Griffin RJ. 1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity. Journal of Medicinal Chemistry 2013, 56(16), 6386-6401.
• Barrett L, Rennison T, Clapham KM, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Dennis M, Finlay R, Golding BT, Hardcastle IR, Newell DR, Young G, Cano C, Griffin RJ. Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK). In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
• Blackburn TJ, Ahmed S, Coxon CR, Liu JF, Lu XH, Golding BT, Griffin RJ, Hutton C, Newell DR, Ojo S, Watson AF, Zaytzev A, Zhao Y, Lunec J, Hardcastle IR. Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions. MedChemComm 2013, 4(9), 1297-1304.
• Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, Lau A, Newell DR, Curtin NJ. Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer. Molecular Cancer Therapeutics 2013, 12(6), 959-967.
• Cully SJ, Blackburn TJ, Cano C, Golding BT, Griffin RJ, Lunec J, Newell D, Noble M, Zhao Y, Hardcastle IR. Regiospecific synthesis of isoindolinones as MDM2 inhibitors. In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
• Mould E, Berry P, Jamieson D, Hill C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells. In: American Association for Cancer Research 104th Annual Meeting. 2013, Washington, DC, USA: American Association for Cancer Research.
• Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice. PLoS ONE 2013, 8(12), e81763.